Literature DB >> 4235015

Red-cell transport defect in patients with cystic fibrosis and in their parents.

J W Balfe, C Cole, L G Welt.   

Abstract

The ouabain-sensitive and the ethacrynic acid-sensitive sodium efflux from erythrocytes of patients with cystic fibrosis are both decreased. Furthermore, the ouabain-sensitive adenosine triphosphatase activity is diminished in the red blood cell ghosts of these patients. Perhaps of greater significance is the fact that ethacrynic acid-sensitive sodium efflux is clearly diminished in the erythrocytes of the asymptomatic parents of these sick children. This defect in sodium transport may be valuable for detecting the heterozygous carrier state.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4235015     DOI: 10.1126/science.162.3854.689

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  6 in total

1.  Studies on the synthesis of plasma membrane proteins of fibroblasts from patients with cystic fibrosis.

Authors:  J E Changus; D O Quissell; M R Sukup; H C Pitot
Journal:  Am J Pathol       Date:  1975-08       Impact factor: 4.307

2.  Cystic fibrosis of the pancreas--new clues to the metabolic riddle.

Authors:  R C Talamo
Journal:  Calif Med       Date:  1969-05

3.  Na and K dependence of the Na/K pump in cystic fibrosis fibroblasts.

Authors:  V M Reznik; J A Schneider; S A Mendoza
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

4.  Cystic fibrosis: normal volumes of red cells. Model experiments on the pathomechanism of the disease.

Authors:  H M Emrich; J Heitz; S Katz; R Thom
Journal:  Eur J Pediatr       Date:  1976-07-12       Impact factor: 3.183

5.  The effects of transport inhibitors on sodium outflux and influx in red blood cells: evidence for exchange diffusion.

Authors:  M J Dunn
Journal:  J Clin Invest       Date:  1970-10       Impact factor: 14.808

6.  Cystic fibrosis of the pancreas. A study in cell culture.

Authors:  B S Danes; A G Bearn
Journal:  J Exp Med       Date:  1969-04-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.